Invesaro

Stocks BVS DCF valuation

DCF valuation

What is Bioventus Inc. worth?

With the base-case assumptions below, a discounted cash flow model on Bioventus Inc.'s reported free cash flow gives $31.39 per share. The share price was $13.81 on September 25, 2026, 56% below that value.

Inputs from the filings

Free cash flow, fiscal 2025
$72.1M
Average free cash flow, last 5 years
$22.5M
Cash
$29.5M
balance sheet of June 27, 2026
Debt
$248.5M
balance sheet of June 27, 2026
Diluted shares, fiscal 2025
68,914,895
Revenue growth per year, last 4 years
15.3%

Three sets of assumptions

CaseGrowth yrs 1-5Growth yrs 6-10After year 10Discount rateValue per shareValue vs price
Bear10.0%6.0%2.0%10.0%$17.83+29%
Base15.0%9.0%2.5%9.0%$31.39+127%
Bull20.0%11.5%3.0%8.0%$56.65+310%

Sensitivity: base case value per share

Discount rate down the side, growth after year 10 across the top. Everything else as in the base case.

1.5%2.0%2.5%3.0%3.5%
7.0%$41.66$44.87$48.78$53.67$59.96
8.0%$33.95$36.03$38.48$41.43$45.03
9.0%$28.34$29.76$31.39$33.31$35.56
10.0%$24.08$25.09$26.23$27.54$29.05
11.0%$20.75$21.49$22.32$23.25$24.30

Where the presets come from

Base: years 1 to 5 grow at Bioventus Inc.'s revenue growth rate over the last 4 fiscal years (15.3% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.

Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.

Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.

This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.

Adjust the assumptions

Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.

Adjust the assumptions

Bioventus Inc. company page